Funding
Psychedelic biotech startup Psylo raises $1.1m to treat mental health issues with the key ingredient in magic mushrooms
Psylo, a preclinical biotech firm, has raised $1.1 million as part of an ambitious plan to treat mental illness with naturally occurring psychedelic drugs. The Sydney-based startup, part of Startmate‘s current W21 cohort, has been backed in a round led led by Chris Hitchen’s global micro-VC fund Possible Ventures. The venture’s prominent angel investors also include Airtree’s… Read more »
